Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2010

Open Access 01-12-2010 | Research

Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis

Authors: Tatsuya Tanaka, Hideyuki Ishiguro, Yoshiyuki Kuwabara, Masahiro Kimura, Akira Mitsui, Takeyasu Katada, Midori Shiozaki, Yasuhiro Naganawa, Yoshitaka Fujii, Hiromitsu Takeyama

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2010

Login to get access

Abstract

Background

The diagnosis of lymph node metastasis in esophageal cancer by the presence and number of metastatic lymph nodes is an extremely important prognostic factor. In addition, the indication of non-surgical therapy is gaining more attention. Vascular endothelial growth factor C (VEGF-C) is potentially lymphangiogenic and selectively induces hyperplasia of the lymphatic vasculature. In this study, we investigated the expression of VEGF-C and whether it correlated with various clinico-pathologic findings.

Methods

KYSE series of esophageal cancer cell lines and 106 patients with primary esophageal squamous cell carcinomas who had undergone radical esophagectomy were analyzed. VEGF-C mRNA expression was determined by quantitative RT-PCR.

Results

High expression of VEGF-C was detected in most of the KYSE cell lines, especially KYSE410, yet, in an esophageal normal epithelium cell line, Het-1A, VEGF-C was not detected. In the clinical specimen, the expression of VEGF-C in the cancerous tissue was higher than in the corresponding noncancerous esophageal mucosa (p = 0.026). The expression of VEGF-C was found to be higher in Stage2B-4A tumors than in Stage0-2A tumors (p = 0.049). When the patients were divided into two groups according to their expression levels of VEGF-C (a group of 53 cases with high expression and a group of 53 cases with low expression), the patients with high VEGF-C expression had significantly shorter survival after surgery than the patients with low expression (p = 0.0065). Although univariate analysis showed that high expression of VEGF-C was a statistically significant prognostic factor, this was not shown in multivariate analysis. In the subgroup of patients with Tis and T1 tumors, the expression of VEGF-C was higher in N1 tumors than in N0 tumors (p = 0.029). The survival rate of patients from the high expression group (n = 10) was lower than that in the low expression group (n = 11), and all the patients in the low VEGF-C expression group survived.

Conclusions

The expression of VEGF-C correlates with lymph node metastasis and poor prognosis. In patients with Tis and T1 esophageal tumors, the expression of VEGF-C may be a good diagnostic factor for determining metastasis of the lymph node.
Appendix
Available only for authorised users
Literature
1.
go back to reference Maesawa C, Tamura G, Suzuki Y, Ogasawara S, Ishida K, Saito K, Satodate R: Aberrations of tumor-suppressor genes (p53, apc, mcc and Rb) in esophageal squamous-cell carcinoma. Int J Cancer. 1994, 57: 21-25. 10.1002/ijc.2910570105.CrossRef Maesawa C, Tamura G, Suzuki Y, Ogasawara S, Ishida K, Saito K, Satodate R: Aberrations of tumor-suppressor genes (p53, apc, mcc and Rb) in esophageal squamous-cell carcinoma. Int J Cancer. 1994, 57: 21-25. 10.1002/ijc.2910570105.CrossRef
2.
go back to reference Dolan K, Garde J, Walker SJ, Sutton R, Gosney J, Field JK: LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus. Hum Pathol. 1999, 30: 1508-1514. 10.1016/S0046-8177(99)90175-2.CrossRef Dolan K, Garde J, Walker SJ, Sutton R, Gosney J, Field JK: LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus. Hum Pathol. 1999, 30: 1508-1514. 10.1016/S0046-8177(99)90175-2.CrossRef
3.
go back to reference Nishiwaki T, Daigo Y, Kawasoe T, Nakamura Y: Isolation and mutational analysis of a novel human cDNA, DEC1 (deleted in esophageal cancer 1), derived from the tumor suppressor locus in 9q32. Genes Chromosomes Cancer. 2000, 27: 169-176. 10.1002/(SICI)1098-2264(200002)27:2<169::AID-GCC8>3.0.CO;2-M.CrossRef Nishiwaki T, Daigo Y, Kawasoe T, Nakamura Y: Isolation and mutational analysis of a novel human cDNA, DEC1 (deleted in esophageal cancer 1), derived from the tumor suppressor locus in 9q32. Genes Chromosomes Cancer. 2000, 27: 169-176. 10.1002/(SICI)1098-2264(200002)27:2<169::AID-GCC8>3.0.CO;2-M.CrossRef
4.
go back to reference Miyake S, Nagai K, Yoshino K, Oto M, Endo M, Yuasa Y: Point mutations and allelic deletion of tumor suppressor gene DCC in human esophageal squamous cell carcinomas and their relation to metastasis. Cancer Res. 1994, 54: 3007-3010. Miyake S, Nagai K, Yoshino K, Oto M, Endo M, Yuasa Y: Point mutations and allelic deletion of tumor suppressor gene DCC in human esophageal squamous cell carcinomas and their relation to metastasis. Cancer Res. 1994, 54: 3007-3010.
5.
go back to reference Daigo Y, Nishiwaki T, Kawasoe T, Tamari M, Tsuchiya E, Nakamura Y: Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21.3. Cancer Res. 1999, 59: 1966-1972. Daigo Y, Nishiwaki T, Kawasoe T, Tamari M, Tsuchiya E, Nakamura Y: Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21.3. Cancer Res. 1999, 59: 1966-1972.
6.
go back to reference Research Committee on Malignancy of Esophageal Cancer, Japanese Society for Esophageal Diseases: Prognostic significance of CyclinD1 and E-Cadherin in patients with esophageal squamous cell carcinoma: multiinstitutional retrospective analysis. J Am Coll Surg. 2001, 192: 708-718. 10.1016/S1072-7515(01)00840-7.CrossRef Research Committee on Malignancy of Esophageal Cancer, Japanese Society for Esophageal Diseases: Prognostic significance of CyclinD1 and E-Cadherin in patients with esophageal squamous cell carcinoma: multiinstitutional retrospective analysis. J Am Coll Surg. 2001, 192: 708-718. 10.1016/S1072-7515(01)00840-7.CrossRef
7.
go back to reference Itami A, Shimada Y, Watanabe G, Imamura M: Prognostic value of p27(Kip1) and CyclinD1 expression in esophageal cancer. Oncology. 1999, 57: 311-317. 10.1159/000012067.CrossRef Itami A, Shimada Y, Watanabe G, Imamura M: Prognostic value of p27(Kip1) and CyclinD1 expression in esophageal cancer. Oncology. 1999, 57: 311-317. 10.1159/000012067.CrossRef
8.
go back to reference Souza RF, Garrigue-Antar L, Lei J, Yin J, Appel R, Vellucci VF, Zou TT, Zhou X, Wang S, Rhyu MG, Cymes K, Chan O, Park WS, Krasna MJ, Greenwald BD, Cottrell J, Abraham JM, Simms L, Leggett B, Young J, Harpaz N, Reiss M, Meltzer SJ: Alterations of transforming growth factor-beta 1 receptor type II occur in ulcerative colitis-associated carcinomas, sporadic colorectal neoplasms, and esophageal carcinomas, but not in gastric neoplasms. Hum Cell. 1996, 9: 229-236. Souza RF, Garrigue-Antar L, Lei J, Yin J, Appel R, Vellucci VF, Zou TT, Zhou X, Wang S, Rhyu MG, Cymes K, Chan O, Park WS, Krasna MJ, Greenwald BD, Cottrell J, Abraham JM, Simms L, Leggett B, Young J, Harpaz N, Reiss M, Meltzer SJ: Alterations of transforming growth factor-beta 1 receptor type II occur in ulcerative colitis-associated carcinomas, sporadic colorectal neoplasms, and esophageal carcinomas, but not in gastric neoplasms. Hum Cell. 1996, 9: 229-236.
9.
go back to reference Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, Yin J, Fleisher AS, Abraham JM, Beer DG, Sidransky D, Huss HT, Demeester TR, Eads C, Laird PW, Ilson DH, Kelsen DP, Harpole D, Moore MB, Danenberg KD, Danenberg PV, Meltzer SJ: Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst. 2000, 92: 1805-1811. 10.1093/jnci/92.22.1805.CrossRef Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, Yin J, Fleisher AS, Abraham JM, Beer DG, Sidransky D, Huss HT, Demeester TR, Eads C, Laird PW, Ilson DH, Kelsen DP, Harpole D, Moore MB, Danenberg KD, Danenberg PV, Meltzer SJ: Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst. 2000, 92: 1805-1811. 10.1093/jnci/92.22.1805.CrossRef
10.
go back to reference Boynton RF, Blount PL, Yin J, Brown VL, Huang Y, Tong Y, McDaniel T, Newkirk C, Resau JH, Raskind WH, Haggitt RC, Reid BJ, Meltzer SJ: Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci USA. 1992, 89: 3385-3388. 10.1073/pnas.89.8.3385.CrossRef Boynton RF, Blount PL, Yin J, Brown VL, Huang Y, Tong Y, McDaniel T, Newkirk C, Resau JH, Raskind WH, Haggitt RC, Reid BJ, Meltzer SJ: Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci USA. 1992, 89: 3385-3388. 10.1073/pnas.89.8.3385.CrossRef
11.
go back to reference Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J, Fujii Y: Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 2001, 95: 92-95. 10.1002/1097-0215(20010320)95:2<92::AID-IJC1016>3.0.CO;2-9.CrossRef Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J, Fujii Y: Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 2001, 95: 92-95. 10.1002/1097-0215(20010320)95:2<92::AID-IJC1016>3.0.CO;2-9.CrossRef
12.
go back to reference Shimada Y, Imamura M, Shibagaki I, Tanaka H, Miyahara T, Kato M, Ishizaki K: Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy. Ann Surg. 1997, 226: 162-168. 10.1097/00000658-199708000-00007.CrossRef Shimada Y, Imamura M, Shibagaki I, Tanaka H, Miyahara T, Kato M, Ishizaki K: Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy. Ann Surg. 1997, 226: 162-168. 10.1097/00000658-199708000-00007.CrossRef
13.
go back to reference Plate K: From angiogenesis to lymphangiogenesis. Nat Med. 2001, 7: 151-152. 10.1038/84579.CrossRef Plate K: From angiogenesis to lymphangiogenesis. Nat Med. 2001, 7: 151-152. 10.1038/84579.CrossRef
14.
go back to reference Sobin LH, Wittekind C: TNM classification of malignant tumor. 2002, New Jersey: John Wiley and Sons, six edn Sobin LH, Wittekind C: TNM classification of malignant tumor. 2002, New Jersey: John Wiley and Sons, six edn
15.
go back to reference Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev. 1997, 18: 4-25. 10.1210/er.18.1.4.CrossRef Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev. 1997, 18: 4-25. 10.1210/er.18.1.4.CrossRef
16.
go back to reference Su JL, Yen CJ, Chen PS, Chuang SE, Hong CC, Kuo IH, Chen HY, Hung MC, Kuo ML: The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer. 2007, 96: 541-545. 10.1038/sj.bjc.6603487.CrossRef Su JL, Yen CJ, Chen PS, Chuang SE, Hong CC, Kuo IH, Chen HY, Hung MC, Kuo ML: The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer. 2007, 96: 541-545. 10.1038/sj.bjc.6603487.CrossRef
17.
go back to reference Juttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W, Hocker M: Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol. 2006, 24: 228-240. 10.1200/JCO.2004.00.3467.CrossRef Juttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W, Hocker M: Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol. 2006, 24: 228-240. 10.1200/JCO.2004.00.3467.CrossRef
18.
go back to reference Van Trappen PO, Steele D, Lowe DG, Baithun S, Beasley N, Thiele W, Weich H, Krishnan J, Shepherd JH, Pepper MS, Jackson DG, Sleeman JP, Jacobs IJ: Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol. 2003, 201: 544-554. 10.1002/path.1467.CrossRef Van Trappen PO, Steele D, Lowe DG, Baithun S, Beasley N, Thiele W, Weich H, Krishnan J, Shepherd JH, Pepper MS, Jackson DG, Sleeman JP, Jacobs IJ: Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol. 2003, 201: 544-554. 10.1002/path.1467.CrossRef
19.
go back to reference Witte D, Thomas A, Ali N, Carlson N, Younes M: Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer Res. 2002, 22: 1463-1466. Witte D, Thomas A, Ali N, Carlson N, Younes M: Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer Res. 2002, 22: 1463-1466.
20.
go back to reference Neuchrist C, Erovic BM, Handisurya A, Fischer MB, Steiner GE, Hollemann D, Gedlicka C, Saaristo A, Burian M: Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck. 2003, 25: 464-474. 10.1002/hed.10235.CrossRef Neuchrist C, Erovic BM, Handisurya A, Fischer MB, Steiner GE, Hollemann D, Gedlicka C, Saaristo A, Burian M: Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck. 2003, 25: 464-474. 10.1002/hed.10235.CrossRef
21.
go back to reference Ishikawa M, Kitayama J, Kazama S, Nagawa H: The expression pattern of vascular endothelial growth factor C and D in human esophageal normal mucosa, dysplasia and neoplasia. Hepatogastroenterology. 2004, 51: 1319-1322. Ishikawa M, Kitayama J, Kazama S, Nagawa H: The expression pattern of vascular endothelial growth factor C and D in human esophageal normal mucosa, dysplasia and neoplasia. Hepatogastroenterology. 2004, 51: 1319-1322.
22.
go back to reference Ding MX, Lin XQ, Fu XY, Zhang N, Li JC: Expression of vascular endothelial growth factor-C and angiogenesis in esophageal squamous cell carcinoma. World J Gastroenterol. 2006, 12: 4582-4585. Ding MX, Lin XQ, Fu XY, Zhang N, Li JC: Expression of vascular endothelial growth factor-C and angiogenesis in esophageal squamous cell carcinoma. World J Gastroenterol. 2006, 12: 4582-4585.
23.
go back to reference Okazawa T, Yoshida T, Shirai Y, Shiraishi R, Harada T, Sakaida I, Abe T, Oka M: Expression of vascular endothelial growth factor C is a prognostic indicator in esophageal cancer. Hepatogastroenterology. 2008, 55: 1503-1508. Okazawa T, Yoshida T, Shirai Y, Shiraishi R, Harada T, Sakaida I, Abe T, Oka M: Expression of vascular endothelial growth factor C is a prognostic indicator in esophageal cancer. Hepatogastroenterology. 2008, 55: 1503-1508.
24.
go back to reference Minashi K, Muto M, Ohtsu A: Nonsurgical treatments for submucosal esophageal squamous cell carcinomas. Esophagus. 2007, 4: 159-164. 10.1007/s10388-007-0138-4.CrossRef Minashi K, Muto M, Ohtsu A: Nonsurgical treatments for submucosal esophageal squamous cell carcinomas. Esophagus. 2007, 4: 159-164. 10.1007/s10388-007-0138-4.CrossRef
25.
go back to reference Arima M, Arima H, Tada M, Tanaka Y: Diagnostic accuracy of tumor staging and treatment outcomes in patients with superficial esophageal cancer. Esophagus. 2007, 4: 145-153. 10.1007/s10388-007-0136-6.CrossRef Arima M, Arima H, Tada M, Tanaka Y: Diagnostic accuracy of tumor staging and treatment outcomes in patients with superficial esophageal cancer. Esophagus. 2007, 4: 145-153. 10.1007/s10388-007-0136-6.CrossRef
26.
go back to reference Pech O, May A, Gunter E, Gossner L, Ell C: The impact of endoscopic ultrasound and computed tomography on the TNM staging of early cancer in Barrett's esophagus. Am J Gastroenterol. 2006, 101: 2223-2229. 10.1111/j.1572-0241.2006.00718.x.CrossRef Pech O, May A, Gunter E, Gossner L, Ell C: The impact of endoscopic ultrasound and computed tomography on the TNM staging of early cancer in Barrett's esophagus. Am J Gastroenterol. 2006, 101: 2223-2229. 10.1111/j.1572-0241.2006.00718.x.CrossRef
27.
go back to reference Kim K, Park SJ, Kim BT, Lee KS, Shim YM: Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thorac Surg. 2001, 71: 290-294. 10.1016/S0003-4975(00)02221-9.CrossRef Kim K, Park SJ, Kim BT, Lee KS, Shim YM: Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thorac Surg. 2001, 71: 290-294. 10.1016/S0003-4975(00)02221-9.CrossRef
28.
go back to reference Yoon YC, Lee KS, Shim YM, Kim BT, Kim K, Kim TS: Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study. Radiology. 2003, 227: 764-770. 10.1148/radiol.2281020423.CrossRef Yoon YC, Lee KS, Shim YM, Kim BT, Kim K, Kim TS: Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study. Radiology. 2003, 227: 764-770. 10.1148/radiol.2281020423.CrossRef
Metadata
Title
Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis
Authors
Tatsuya Tanaka
Hideyuki Ishiguro
Yoshiyuki Kuwabara
Masahiro Kimura
Akira Mitsui
Takeyasu Katada
Midori Shiozaki
Yasuhiro Naganawa
Yoshitaka Fujii
Hiromitsu Takeyama
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2010
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-29-83

Other articles of this Issue 1/2010

Journal of Experimental & Clinical Cancer Research 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine